Elranatamab + Lenalidomide + Dexamethasone for Multiple Myeloma
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial aims to assess how a combination of three drugs—Elranatamab, Lenalidomide, and Dexamethasone—affects individuals newly diagnosed with multiple myeloma, a type of blood cancer. Researchers seek to determine if this combination can improve health outcomes. Individuals recently diagnosed with multiple myeloma who exhibit specific symptoms, such as bone pain or changes in blood tests, might be suitable candidates for this study. As a Phase 2 trial, the research focuses on evaluating the treatment's effectiveness in an initial, smaller group, providing participants an opportunity to contribute to significant medical advancements.
Do I have to stop taking my current medications for the trial?
The trial protocol does not specify if you need to stop taking your current medications. However, there is a 2-week washout period required for certain prior treatments. It's best to discuss your specific medications with the trial team.
Is there any evidence suggesting that this trial's treatments are likely to be safe?
Research has shown that combining elranatamab with lenalidomide and dexamethasone is generally safe and manageable for patients with newly diagnosed multiple myeloma. One study found this combination to be well-tolerated, although some common side effects occurred. These included low levels of white blood cells, red blood cells, and platelets, which are typical and expected with such treatments. Overall, the findings support the treatment's safety, though participants may still experience these side effects.12345
Why do researchers think this study treatment might be promising?
Elranatamab is unique because, unlike many standard treatments for multiple myeloma, it is a bispecific antibody that targets two different proteins on cancer cells. This dual-targeting approach allows it to more effectively engage the immune system to attack and destroy myeloma cells. Researchers are excited about Elranatamab because it offers a novel mechanism of action, potentially providing a more powerful and efficient way to treat multiple myeloma compared to traditional therapies like proteasome inhibitors and immunomodulatory drugs. By combining it with lenalidomide and dexamethasone, there's hope for enhanced treatment efficacy and improved patient outcomes.
What evidence suggests that this treatment might be an effective treatment for Multiple Myeloma?
Research has shown that combining Elranatamab, Lenalidomide, and Dexamethasone may help treat multiple myeloma. In studies, this treatment showed early positive results in newly diagnosed patients who cannot undergo transplants, suggesting it might effectively manage the disease. The combination likely works well by attacking cancer cells in different ways, potentially improving disease control. Although more information is needed, these early results offer promise for those considering this treatment option.45678
Who Is on the Research Team?
Carl O Landgren, MD
Principal Investigator
Professor of Medicine
Are You a Good Fit for This Trial?
This trial is for individuals newly diagnosed with Multiple Myeloma, a type of blood cancer. Participants should meet specific health criteria set by the study team but these are not detailed here.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive Elranatamab in combination with Lenalidomide and Dexamethasone (ERd) for up to 24 cycles
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Elranatamab
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Miami
Lead Sponsor
Pfizer
Industry Sponsor
Albert Bourla
Pfizer
Chief Executive Officer since 2019
PhD in Biotechnology of Reproduction, Aristotle University of Thessaloniki
Patrizia Cavazzoni
Pfizer
Chief Medical Officer
MD from McGill University